Niki BioSolutions, Inc. NIKI
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -15.50% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -77.70% | -- | -- | -- |
| Total Operating Expenses | -- | -59.02% | -- | -- | -- |
| Operating Income | -- | 59.02% | -- | -- | -- |
| Income Before Tax | -- | 18.59% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | 18.59% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -158.40% | -- | -- | -- |
| Net Income | -- | 2.03% | -- | -- | -- |
| EBIT | -- | 59.02% | -- | -- | -- |
| EBITDA | -- | 59.21% | -- | -- | -- |
| EPS Basic | -- | 14.83% | -- | -- | -- |
| Normalized Basic EPS | -- | 69.85% | -- | -- | -- |
| EPS Diluted | -- | 14.29% | -- | -- | -- |
| Normalized Diluted EPS | -- | 69.85% | -- | -- | -- |
| Average Basic Shares Outstanding | -- | 26.23% | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | 26.23% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |